{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride&page=3",
    "query": {
      "intervention": "0.9% Sodium Chloride",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 2427,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T06:17:59.491Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04501978",
      "title": "ACTIV-3: Therapeutics for Inpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "LY3819253",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VIR-7831",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BRII-196/BRII-198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MP0420",
          "type": "DRUG"
        },
        {
          "name": "PF-07304814",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2753,
      "start_date": "2020-08-04",
      "completion_date": "2023-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 98,
      "location_summary": "Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501978"
    },
    {
      "nct_id": "NCT03928496",
      "title": "Abobotulinumtoxina Efficacy in Post-Traumatic Headache",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post-Traumatic Headache"
      ],
      "interventions": [
        {
          "name": "AbobotulinumtoxinA",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Greater Los Angeles Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-08-01",
      "completion_date": "2017-02-02",
      "has_results": false,
      "last_update_posted_date": "2019-04-26",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03928496"
    },
    {
      "nct_id": "NCT03988023",
      "title": "Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "Ampion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ampio Pharmaceuticals. Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 1043,
      "start_date": "2019-06-24",
      "completion_date": "2021-07-13",
      "has_results": true,
      "last_update_posted_date": "2022-10-05",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 1,
      "location_summary": "Englewood, Colorado",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988023"
    },
    {
      "nct_id": "NCT03122223",
      "title": "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV (vCP2438)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/AS01(B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 160,
      "start_date": "2018-01-16",
      "completion_date": "2020-07-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03122223"
    },
    {
      "nct_id": "NCT04317040",
      "title": "Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Disease 2019 (COVID-19)"
      ],
      "interventions": [
        {
          "name": "Efprezimod alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2020-04-24",
      "completion_date": "2020-10-20",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 10,
      "location_summary": "Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04317040"
    },
    {
      "nct_id": "NCT03203174",
      "title": "The Use of Microneedles With Topical Botulinum Toxin for Treatment of Palmar Hyperhidrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperhidrosis"
      ],
      "interventions": [
        {
          "name": "Microneedle",
          "type": "DEVICE"
        },
        {
          "name": "Sham Microneedle",
          "type": "DEVICE"
        },
        {
          "name": "Botulinum Toxin Type A",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-01",
      "completion_date": "2016-08-02",
      "has_results": false,
      "last_update_posted_date": "2017-07-19",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03203174"
    },
    {
      "nct_id": "NCT01603459",
      "title": "Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spasticity of the Upper and Lower Limb Due to Cerebral Causes"
      ],
      "interventions": [
        {
          "name": "IncobotulinumtoxinA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Pharmaceuticals GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 155,
      "start_date": "2012-05",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 6,
      "location_summary": "Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01603459"
    },
    {
      "nct_id": "NCT00005908",
      "title": "Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasm"
      ],
      "interventions": [
        {
          "name": "Docetaxel - Dose A",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel - Dose B",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine - Dose B",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine - Dose A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2000-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2013-03-19",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005908"
    },
    {
      "nct_id": "NCT01990820",
      "title": "Study for the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinuplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rhinitis + Sinusitis, Pediatric Chronic Rhinosinusitis"
      ],
      "interventions": [
        {
          "name": "Acclarent Relieva Balloon Sinuplasty",
          "type": "DEVICE"
        },
        {
          "name": "Adenoidectomy + Maxillary Sinus Irrigation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 25,
      "start_date": "2009-03",
      "completion_date": "2016-09-29",
      "has_results": true,
      "last_update_posted_date": "2020-02-19",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01990820"
    },
    {
      "nct_id": "NCT00752050",
      "title": "Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Rhytides",
        "Frown Lines Between the Eyebrows"
      ],
      "interventions": [
        {
          "name": "Mentor Purified Toxin Botulinum Toxin Type A",
          "type": "DRUG"
        },
        {
          "name": "Preservative-free Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mentor Worldwide, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 699,
      "start_date": "2007-11",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2011-09-12",
      "last_synced_at": "2026-10-17T06:17:59.491Z",
      "location_count": 1,
      "location_summary": "Santa Barbara, California",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00752050"
    }
  ]
}